万维提示：
1、投稿方式：在线投稿。
2、期刊网址：
https://onlinelibrary.wiley.com/journal/19341563
3、投稿网址：https://mc.manuscriptcentral.com/pmr
4、官网邮箱：pmrjournal@wiley.com
PMRJ@wiley.com
5、期刊刊期：月刊，一年出版十二期。
2021年5月20日星期四
投稿须知【官网信息】
PM&R AUTHOR GUIDELINES
1. Journal Aims and Scope
PM&R is the official scientific journal of the American Academy of Physical Medicine and Rehabilitation (AAPM&R). It is a monthly, peer reviewed, scholarly publication. The journal is an internationally leading journal that advances the specialty of physical medicine and rehabilitation by publishing interdisciplinary disability-related research that highlights the value that physical medicine and rehabilitation brings to the care of patients in diverse settings, medical fields and across a wide variety of conditions. Contributions from all parts of the world and from all types of professions in rehabilitation are therefore encouraged.
Topics covered include acute and chronic musculoskeletal disorders and pain, neurologic conditions involving the central and peripheral nervous systems, rehabilitation of impairments associated with disabilities in adults and children, and neurophysiology and electrodiagnosis. PM&R emphasizes principles of injury, function, and rehabilitation, and is designed to be relevant to practitioners and researchers in a variety of medical and surgical specialties and rehabilitation disciplines including allied health.
The content of PM&R includes articles that are contemporary and important to both research and clinical practice. The various sections of the journal include original research such as clinical trials, outcomes studies, and clinically relevant translational science; reviews (narrative and analytical); case presentations; point/counterpoint debates; ethical legal feature topics; practice management updates; statistical and research methodology themes; editorial and opinion pieces; images; clinical pearls; emerging issues; and letters to the editor.
2. Submission
Authors should note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.
Once the submission materials have been prepared in accordance with the Author Guidelines, manuscripts should be submitted online at https://mc.manuscriptcentral.com/pmr
For more details on how to use ScholarOne, please visit http://mchelp.manuscriptcentral.com/gethelpnow/
Data protection:
By submitting a manuscript to or reviewing for PM&R, your contact information, which may include name, email address, and affiliation, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. PM&R and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices.wiley.com/statements/data-protection-policy.html.
For help with submissions, please contact the journal Editorial Office at pmrjournal@wiley.com
3. Manuscript Categories and Requirements
Original Research
Original research manuscripts should be limited to 4,000 words excluding references, tables and figures. All original research manuscripts must be accompanied by a structured abstract of no more than 300 words.
Abstracts for Original Research Manuscripts:
Introduction: Provide 2-3 sentences that describe the reason for this study, including the knowledge gap in the literature and how this study is designed to fill that gap.
Objective: State the main question or objective of the study and the major a prior hypothesis tested if applicable.
Design: Describe the design of the study using the appropriate terms below.
Intervention studies: randomized controlled trial (see Glossary for the definition of this and other technical terms); nonrandomized controlled trial; double-blind; placebo control; crossover trial; and/or before-after trial.
For studies of screening and diagnostic tests: criterion standard (ie, a widely accepted standard with which a new or alternative test is being compared; this term is preferred to gold standard); and/or blinded or masked comparison.
For studies of prognosis: inception cohort (participants assembled at a similar and early time in the course of the disorder and followed thereafter); cohort (participants followed forward in time, but not necessarily from a common starting point); and/or validation cohort or validation sample of the study involves the modeling of clinical predictions.
For studies of causation: randomized controlled trial; cohort; case control
For descriptions of the clinical features of medical disorders: survey; and/or case series.
For studies that include a formal economic evaluation: cost-effectiveness analysis; cost-utility analysis; and/or cost-benefit analysis. For new analyses of existing data sets, the data set should be named and the basic study design disclosed.
Setting: Indicate the study setting, including the level of clinical care (eg, primary or tertiary, private practice or institutional).
Patients (or Participants): State selection procedures, entry criteria, and numbers of participants entering and finishing the study.
Interventions: Describe essential features of any interventions, including their method and duration of administration. For observational studies, clearly describe the independent variables. If the study does not contain any interventions, then the following form should be used: Interventions: Not applicable.
Main Outcome Measure(s): The primary study outcome measures (dependent variables) should be indicated as planned before data collection began. If the hypothesis being reported was formulated during or after data collection, this fact should be clearly stated.
Results: Report the main findings of the study. Results should be accompanied by CIs (eg, 95%) and the exact level of statistical significance. For comparative studies, CIs should relate to the differences between groups. For nonsignificant differences for the major study outcome measure(s), state the clinically important difference sought and give the CI for the difference between the groups. When risk changes or effect sizes are given, indicate absolute values so that readers can determine the absolute as well as relative impact of the finding. Approaches such as number needed to treat to achieve a unit of benefit are encouraged when appropriate; reporting of relative differences alone is usually inappropriate. If appropriate, studies of screening and diagnostic tests should use the terms sensitivity, specificity, and likelihood ratio. If predictive values or accuracy are given, give prevalence or pretest likelihood as well. Report no data in the abstract that do not appear in the article.
Conclusions: State only those conclusions of the study that are directly supported by data, along with their clinical application (avoiding overgeneralization) or whether additional study is required before the information should be used in usual clinical settings.
The main text should include the following sections: introduction, methods, results, discussion and conclusion.
Introduction: Describe the reason for this study, including the knowledge gap in the literature and how this study is designed to fill that gap.
Methods: The methods section should include enough detailed information to replicate the basic study design. The methods section should contain an overall description of the study design, study participants, inclusion/exclusion criteria, pre-determined subgroups, procedures, outcome measures and statistical analyses. Both randomized and observational studies should identify the primary outcome(s) before the study began, as well as any pre-specified secondary, subgroup, and/or sensitivity analyses. In the Methods section, describe statistical methods with enough detail to enable a knowledgeable reader with access to the original data to reproduce the reported results. Such description should include appropriate references to the original literature, particularly for uncommon statistical methods. For more advanced or novel methods, provide a brief explanation of the methods and appropriate use in the text and consider providing a detailed description in an online supplement.
Report the main findings of the study. Results should be accompanied by CIs (eg,95%) and the exact level of statistical significance. For comparative studies, CIs should relate to the differences between groups. For nonsignificant differences for the major study outcome measure(s), state the clinically important difference sought and give the CI for the difference between the groups. When risk changes or effect sizes are given, indicate absolute values so that readers can determine the absolute as well as relative impact of the finding. Approaches such as number needed to treat to achieve a unit of benefit are encouraged when appropriate; reporting of relative differences alone is usually inappropriate. If appropriate, studies of screening and diagnostic tests should use the terms sensitivity, specificity, and likelihood ratio. If predictive values or accuracy are given, give prevalence or pretest likelihood as well. Report no data in the abstract that do not appear in the article.
For observational studies, provide the numbers of observations. For randomized trials, provide the numbers randomized. Report losses to observation or follow up. For multivariable models, report all variables included in models, and report model diagnostics and overall fit of the model when available. Define statistical terms, abbreviations, and symbols, if included. Avoid nontechnical uses of technical terms in statistics, such as correlation, normal, predictor, random, sample, significant, trend. Do not use inappropriate hedge terms such as marginal significance or trend toward significance for results that are not statistically significant. Causal language (including use of terms such as effect and efficacy) should be used only for randomized clinical trials. For all other study designs (including meta-analyses of randomized clinical trials), methods and results should be described in terms of association or correlation and should avoid cause-and-effect wording.
For randomized trials, a statement of the power or sample size calculation is required (see the EQUATOR Network CONSORT Guidelines). For observational studies that use an established population, a power calculation is not generally required when the sample size is fixed. However, if the sample size was determined by the researchers, through any type of sampling or matching, then there should be some justification for the number sampled. In any case, describe power and sample size calculations at the beginning of the Statistical Methods section, following the general description of the study population.
Discussion: Briefly summarize the key findings, the conclusions and the clinical implications of the findings. Briefly compare and contrast the findings to other published literature. Do not repeat in detail background information or data that has already been presented in the introduction or the Results sections. Do not introduce any new data or findings that have not been presented in the Results section. Make sure that the conclusions stated draw directly from the results of the study as presented. Authors should address the magnitude of the findings including both the statistical and clinical implications of the research.
Limitations: Discuss the limitations of the study.
Conclusions: State only those conclusions of the study that are directly supported by data, along with their clinical application (avoiding overgeneralization) or whether additional study is required before the information should be used in usual clinical settings.
Systematic Reviews and Meta-Analyses
Reviews that systematically find, select, critique, and synthesize evidence relevant to well-defined questions about diagnosis, prognosis, or therapy.
Word limit: limited to 5,000 words, excluding references, tables, and figures.
An Analytical Review (Systematic Reviews and Meta-Analyses) Includes:
Structured abstract
Objective: state the primary objective of the review article.
Literature Survey: include data sources, constraints, and time parameters
Methodology: summarize data extraction and analysis including whether a meta analysis was performed.
Synthesis: describe the main results
Conclusions: state primary conclusion(s) and clinical applicability
Main text:
Introduction (including a statement of purpose)
Methodology (including detailed description of literature search strategy and data abstraction)
Discussion
In depth assessment of published literature ("evidence")
Emphasis on appraisal of quality, synthesis of information, and analysis/comparison of results or conclusions
Conclusion stating a summary of the review including clinical applicability
Systematic Review: Uses explicit methods to search, appraise, and synthesize research evidence in order to address a specific study question. The guidelines provided by the Cochrane Collaboration or the NHS Centre for Reviews and Dissemination are often followed, particularly grading of strength (quality) of evidence. The process is transparent in the reporting of its methods to facilitate others to replicate the process. Systematic reviews seek to draw together all available knowledge on a topic area, requiring an exhaustive, comprehensive literature search. The analysis leads to a determination of what is known and unknown about the study question, and leads to recommendations for future research.
Meta-Analysis: A meta-analysis is often performed as part of a systematic review. A metaanalysis is a statistical analysis that combines the results of quantitative studies to provide a more precise estimate of the effect, answer questions not posed by individual studies or to settle controversies arising from apparently conflicting studies. A high-quality systematic review is essential to a meta-analysis of the literature. Examining heterogeneity among the included studies is critical. If there is substantial heterogeneity among the studies, interpretation of the summary measures must be done cautiously.
[Review Format definitions used/modified with permission from Grant MJ, Booth A. A typology of reviews: an analysis of the 14 review article types and associated methodologies. Health Information and Libraries Journal 2009;26:91-108. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1471-1842.2009.00848.x/full. Accessed April 17, 2012.]
Narrative Reviews
Review articles that use informal methods to collect and interpret information, which is often summarized subjectively in narrative form.
Word limit: limited to 5,000 words, excluding references, tables, and figures.
Narrative reviews include the following:
Non-structured abstract (maximum 250 words)
Introduction (including a statement of purpose)
Literature review, including search strategy with inclusion and exclusion criteria
Discussion, including summary of published evidence
Conclusion, including clinical applicability
Tables and figures useful to present data
Clinical Letters
Clinical letters can include case studies, brief vignettes or case series reporting on a new or rare syndrome or medical condition, a new or emerging diagnostic method, can highlight a previously unrecognized clinical complication or safety issue, or can highlight a novel rehabilitation approach to a medical condition.
The clinical letter does not include an abstract and should be limited to 800 words excluding references, tables and figures. The text should include a brief description of the case or case series and a discussion of why this case is important. The text should not contain headers. References should be limited to 10 (ten) and at least one figure or image should be included, but a maximum of two are allowed.
It is a requirement that formal, written permission be secured from the patient(s) of case reports or case series before publication. The purpose of this "informed permission" is to educate the patients of such case reports regarding the nature of disseminating their personal health information, ensuring maximal de-identification and anonymity, and allowing the patient(s) the option of declining such release of information. You must provide a statement on your title page confirming that you have obtained written patient consent. Wiley has a standard patient consent form available for use.
Images
A column presenting images (eg, radiographs, CT, MRI, electrodiagnostic tracings, pathology, physical examination findings) that are unique, interesting, pertinent, and relevant to the understanding of health and disease in the field of physical medicine and rehabilitation. The format should include an introduction section that provides background information on the entity or disease shown in the images followed by an imaging section summarizing the typical or novel imaging findings shown and their relevance to clinical care or research science of no more than 500 words (excluding references) with references limited to 5 (five).
Letters to the editor Letters to the editor are encouraged and will be considered for publication at the Editor-in-Chief's discretion. All letters should be brief (no more than 750 words) and must relate to content published in PM&R. Letters should not reference any unpublished literature and references are limited to no more than 5 (five). Letters are also subject to editorial modification.
Point-Counterpoint
A debate format of a specific question, usually based on a controversial therapeutic intervention, but could include a theoretical dilemma, diagnostic uncertainty, or other topic in physical medicine and rehabilitation, through which two parties with legitimate opposing perspectives present arguments to support their viewpoints.
This column allows more editorial freedom than a critical review, but the basis of these viewpoints should include scientifically sound arguments supported by available medical evidence as well as personal experience and perspective. Each of the two portions of the manuscript should be no greater than 1,500 words (excluding references) with references limited to no more than 15 (fifteen). No abstract is required, but a brief introduction stating the writer's viewpoint should be included as part of the text. Figures and tables are not required.
Practice Management
A column that focuses on a contemporary issue in clinical physiatric practice relating to health policy, business and/or medical issues such as coding and billing, practice innovations and patient safety, and new trends in physiatric education/training after residency/fellowship.
Manuscripts should be no more than 2,500 words and include an introduction, presentation of the main issue(s) including a comprehensive discussion of clinical implications, and a brief conclusion. There should be no more than 15 (fifteen) references and figures or tables should be limited to two.
Quality Improvement and Patient Safety Reports: Quality improvement and patient safety initiatives include systematic approaches to improve the quality of health care provided within health systems. PM&R will consider quality improvement or patient safety submissions if: 1) they demonstrate impact on clinical outcomes relevant for the field of PM&R; 2) processes are described in sufficient detail to be replicated and 3) reports conform to the SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence) guidelines. Quality improvement and patient safety submissions must include a clear description of the problem and rationale for the intervention, demonstrate clinical results of the intervention and novelty of the findings, and be compelling enough to have impact on the field of PM&R. Consideration for peer review and publication is at the discretion of the Editor-in-Chief.
Ethical-Legal Feature Topics
An in-depth assessment of a specific topic in physical medicine and rehabilitation that raises questions and concerns across the medical, ethical, and legal fields. Depending on the topic, the column may include either, or both, an ethical and legal perspective which provides the reader with a unique or new perspective on the subject. (If both a legal and ethical piece are presented, these may represent convergent or divergent ideas). The total word count for this column is 3,000 (excluding references) with references limited to no more than 15 (fifteen). No abstract is required, but a brief introduction stating the purpose of the discussion should be included as part of the text. Figures and tables are not required.
Invited Submissions
PM&R publishes some content that is produced internally and does not represent material that is submitted for peer review by external authors. This material includes special features, such as Invited Perspectives (including International Perspectives), Statistically Speaking and Methodology Matters. These are usually solicited from experts and leaders in the field and are designed to educate and stimulate thought and discussion. Manuscripts should be under 3,000 words. At the Editor-in-Chief's discretion, unsolicited manuscripts will be considered for publication, but it is strongly suggested that potential authors contact the Editorial Office first.
Animal Studies Animal studies will not be considered for publication in PM&R.
4. Preparing the Submission
Cover Letters
Cover letters are not mandatory. However, they may be supplied at the author’s discretion.
Parts of the Manuscript
The manuscript should be submitted in separate files: title page; main text file; figures, tables.
Title Page
The title page should contain:
A short informative title containing the major key words. The title should not contain abbreviations (see Wiley's best practice SEO tips); Do not use overly general titles, declarative titles, titles that include the direction of study results, or questions as titles. For reports of clinical trials, meta-analyses, and systematic reviews, include the type of study as a subtitle (eg, A Randomized Clinical Trial, A Meta-analysis, A Systematic Review). For reports of other types of research, do not include study type or design in the title or subtitle.
A short running title of less than 40 characters;
The full names of the authors and highest academic degree;
The author's institutional affiliations where the work was conducted, with a footnote for the author’s present address if different from where the work was conducted;
Funding source;
Acknowledgments.
Main Text File
As papers are double-blind peer reviewed, the main text file should not include any information that might identify the authors. To facilitate peer review, please add line numbers to the document.
The main text file should be presented in the following order:
Title, abstract (where required), and key words;
Main text;
References (please see limits per article type);
Tables (each table complete with title and footnotes);
Figure legends.
Figures and supporting information should be supplied as separate files.
If you are including an APPENDIX, it must be uploaded separately from the main document and designated it as "supporting information for review and online publication only.
Abstract
Abstracts and keywords are required for some manuscript types. For details on manuscript types that require abstracts and/or keywords, as well as how to prepare them, please refer to the ‘Manuscript Categories and Criteria’ section.
Keywords
Please provide at least 3 keywords. Keywords are listed to choose from during submission.
Main Text
• As papers are double-blind peer reviewed, the main text file should not include any information that might identify the authors.
• The journal uses U.S. spelling; however, authors may submit using either option, as spelling of accepted papers is converted during the production process.
• Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter.
References
Use AMA reference style. References should appear the end of the manuscript. They should be cited in the text in the order of appearance. Cite unpublished data, such as papers submitted but not yet accepted for publication or personal communications, in parentheses in the text.
Tables
Tables should be self-contained and complement, not duplicate, information contained in the text. They should be supplied as editable files, not pasted as images. Legends should be concise but comprehensive – the table, legend, and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.
Figure Legends
Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.
Figures
Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a wide variety of formats, sizes, and resolutions are accepted.
Click here for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.
Additional Files
Appendices
Appendices will be published as online supporting information only. For submission they should be supplied as separate files but referred to in the text.
Supporting Information
Supporting information is information that is not essential to the article but provides greater depth and background. It is hosted online and appears without editing or typesetting. It may include tables, figures, videos, datasets, etc.
Click here for Wiley’s FAQs on supporting information.
Note: if data, scripts, or other artifacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.
General Style Points
Manuscripts should be prepared in accordance with the AMA Manual of Style, 10th edition, and/or the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals.
Abbreviations: In general, terms should not be abbreviated unless they are used repeatedly, and the abbreviation is commonly used and recognized by readers. Initially, use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only. The abbreviations SD (standard deviation) and SE (standard error) require no definition in PM&R.
Units of measurement: Metric units are required. Blood pressures in millimeters of mercury (mmHg) and all hematologic and clinical chemistry measurements using the International System of Units (SI). Visit the Bureau International des Poids et Mesures (BIPM) website for more information about SI units.
Numbers: numbers under 10 are spelled out, except for: measurements with a unit (8mmol/l); age (6 weeks old), or lists with other numbers (11 dogs, 9 cats, 4 gerbils).
Trade Names: Chemical substances should be referred to by the generic name only. Trade names should not be used. Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name and the name and location of the manufacturer in parentheses.
Terms: Since “subject” can have a connotation of experimenting on someone and is not patient-centered, use participant, patient, or adult/child whenever possible.
Information on Wiley's English Language Editing services can be found here.
5. Editorial Policies and Ethical Considerations
Peer Review and Acceptance
The acceptance criteria for all papers are the quality and originality of the research and its significance to journal readership. Except where otherwise stated, manuscripts are double-blind peer reviewed. Papers will only be sent to review if the Editor-in-Chief determines that the paper meets the appropriate quality and relevance requirements.
Wiley's policy on the confidentiality of the review process is available here.
APPEALS PROCESS
Appeals must be made in writing to the editor-in-chief within two weeks of receiving the decision regarding a manuscript. Consideration of the appeal will be based on the appeal letter and the version of the manuscript that was peer reviewed. The decision from the appeal is final.
Permissions
Authors wishing to include figures, tables, or text passages that have already been published elsewhere are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from the authors.
Human Studies and Subjects
For manuscripts reporting medical studies that involve human participants, a statement identifying the ethics committee that approved the study and confirmation that the study conforms to recognized standards is required, for example: Declaration of Helsinki; US Federal Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines for Good Clinical Practice. It should also state clearly in the text that all persons gave their informed consent prior to their inclusion in the study.
Patient anonymity should be preserved. When detailed descriptions, photographs, or videos of faces or identifiable body parts are used that may allow identification, authors should obtain the individual's free prior informed consent. Authors do not need to provide a copy of the consent form to the publisher; however, in signing the author license to publish, authors are required to confirm that consent has been obtained. Wiley has a standard patient consent form available for use. Where photographs are used they need to be cropped sufficiently to prevent human subjects being recognized; black eye bars should not be used as they do not sufficiently protect an individual’s identity).
Clinical Trial Registration
The journal requires that clinical trials are registered in a publicly accessible database prior to the first participant being enrolled in the trial. Authors must include the name of the clinical trial registry and the clinical trial registration number at the end of the abstract.
As of January 1, 2016, manuscripts reporting on clinical trials must be registered prior to the first participant being enrolled in the trial. For the purposes of registration, a clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes. WHO | Clinical trials - World Health Organization https://www.who.int/topics/clinical_trials/en/.
If you submit a manuscript that has included a clinical trial that has not been registered a priori, we will not review your manuscript.
Research Reporting Guidelines
Accurate and complete reporting enables readers to fully appraise research, replicate it, and use it. Authors are required to adhere to recognized research reporting standards. The EQUATOR Network collects more than 370 reporting guidelines for many study types, including for:
• Randomised trials: CONSORT
• Observational studies: STROBE
• Systematic reviews: PRISMA
• Case reports: CARE
• Qualitative research: SRQR
• Diagnostic / prognostic studies: STARD
• Quality improvement studies: SQUIRE
• Economic evaluations: CHEERS
• Study protocols: SPIRIT
• Clinical practice guidelines: AGREE
Conflict of Interest
The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. All actual or perceived conflicts must be disclosed when directly relevant or related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships. Download the disclosure form here and include the completed document with your submission.
Funding
Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: https://www.crossref.org/services/funder-registry/
Authorship
The journal follows the ICMJE definition of authorship, which indicates that authorship be based on the following 4 criteria:
Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
Drafting the work or revising it critically for important intellectual content; AND
Final approval of the version to be published; AND
Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
In addition to being accountable for the parts of the work he or she has done, an author should be able to identify which co-authors are responsible for specific other parts of the work. In addition, authors should have confidence in the integrity of the contributions of their co-authors.
All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be acknowledged. These authorship criteria are intended to reserve the status of authorship for those who deserve credit and can take responsibility for the work. The criteria are not intended for use as a means to disqualify colleagues from authorship who otherwise meet authorship criteria by denying them the opportunity to meet criterion #s 2 or 3. Therefore, all individuals who meet the first criterion should have the opportunity to participate in the review, drafting, and final approval of the manuscript.
Acknowledgments
Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section. Financial and material support should also be mentioned.
Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').
Data Sharing and Data Accessibility
Authors may be asked to provide original study data and statistical code if requested by the editors to assist in the editors' understanding and evaluation of method used. The editors may also request access to study data during the peer-review process, and if no other explanations or justification are provided, may cease consideration of a manuscript if the authors cannot or will not provide the data. These data will be treated confidentially and not shared beyond the editorial staff without specific permission from the authors. When statistical code is provided, it should be well-annotated for comprehension (Localio AR, Goodman SN, Meibohm A, et al. Statistical code to support the scientific story. Ann Intern Med. 2018. doi:10.7326/M17-3431).
The journal encourages authors to share the data and other artefacts supporting the results in the paper by archiving it in an appropriate public repository. Authors should include a data accessibility statement, including a link to the repository they have used, in order that this statement can be published alongside their paper.
Sex/Gender Reporting
Authors are encouraged to provide gender-specific data, when appropriate, when describing outcomes of epidemiologic analyses or clinical trials; or specifically state that there were no gender-based differences. For more information please consult the Institute of Medicine's report on "SEX-SPECIFIC REPORTING OF SCIENTIFIC RESEARCH", which can be accessed at http://www.ncbi.nlm.nih.gov/books/NBK84192/pdf/Bookshelf_NBK84192.pdf.
Publication Ethics
This journal is a member of the Committee on Publication Ethics (COPE). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read Wiley’s Top 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found here.
ORCID
As part of the journal’s commitment to supporting authors at every step of the publishing process, the journal encourages the submitting author (only) to provide an ORCID iD when submitting a manuscript. This takes around 2 minutes to complete. Find more information here.
6. Author Licensing
If a paper is accepted for publication, the author identified as the formal corresponding author will receive an email prompting them to log in to Author Services, where via the Wiley Author Licensing Service (WALS) they will be required to complete a copyright license agreement on behalf of all authors of the paper.
Authors may choose to publish under the terms of the journal’s standard copyright agreement, or open access under the terms of a Creative Commons License.
General information regarding licensing and copyright is available here. To review the Creative Commons License options offered under open access, please click here. (Note that certain funders mandate a particular type of CC license be used; to check this please click here.)
Self-Archiving Definitions and Policies: Note that the journal’s standard copyright agreement allows for self-archiving of different versions of the article under specific conditions. Please click here for more detailed information about self-archiving definitions and policies.
Open Access fees: Authors who choose to publish using open access will be charged a fee. A list of Article Publication Charges for Wiley journals is available here.
Funder Open Access: Please click here for more information on Wiley’s compliance with specific Funder Open Access Policies.
To find out which Created Commons Licenses are available for the journal, click here. To learn more about Creative Commons Licenses and to preview terms and conditions of the agreements, please click here. Note that certain funders mandate a particular type of CC license be used; to check this, please click here.
7. Publication Process After Acceptance
Accepted Articles Received in Production
When an accepted article is received by Wiley’s production team, the corresponding author will receive an email asking them to login or register with Wiley Author Services. The author will be asked to sign a publication license at this point.
Accepted Articles
The journal offers Wiley’s Accepted Articles service for all manuscripts. This service ensures that accepted ‘in press’ manuscripts are published online shortly after acceptance, prior to copy-editing or typesetting. Accepted Articles are published online a few days after final acceptance and appear in PDF format only. They are given a Digital Object Identifier (DOI), which allows them to be cited and tracked and are indexed by PubMed. After the final version article is published (the article of record), the DOI remains valid and can still be used to cite and access the article.
Accepted Articles will be indexed by PubMed; submitting authors should therefore carefully check the names and affiliations of all authors provided in the cover page of the manuscript so it is accurate for indexing. Subsequently, the final copyedited and proofed articles will appear in an issue on Wiley Online Library; the link to the article in PubMed will update automatically.
Proofs
Once the paper is typeset, the author will receive an email notification with full instructions on how to provide proof corrections.
Please note that the author is responsible for all statements made in their work, including changes made during the editorial process – authors should check proofs carefully. Note that proofs should be returned within 48 hours from receipt of first proof.
Early View
The journal offers rapid publication via Wiley’s Early View service. Early View (Online Version of Record) articles are published on Wiley Online Library before inclusion in an issue. Note there may be a delay after corrections are received before the article appears online, as Managing Editors also need to review proofs. Once the article is published on Early View, no further changes to the article are possible. The Early View article is fully citable and carries an online publication date and DOI for citations.
Citing this Article: eLocators
This journal now uses eLocators. eLocators are unique identifies for an article that service the same function page numbers have traditionally served in the print world. When citing this article, please insert the eLocator in place of the page number. For more information, please visit the Author Services eLocator page here.
For queries about your article after acceptance, please contact the Production Editor at PMRJ@wiley.com
8. Post Publication
Access and Sharing
When the article is published online:
The author receives an email alert (if requested).
The link to the published article can be shared through social media.
The author will have free access to the paper (after accepting the Terms & Conditions of use, they can view the article).
For non-open access articles, the corresponding author and co-authors can nominate up to ten colleagues to receive a publication alert and free online access to the article.
Promoting the Article
To find out how to best promote an article, click here.
Measuring the Impact of an Article
Wiley also helps authors measure the impact of their research through specialist partnerships with Kudos and Altmetric.
For help with submissions, please contact the journal Editorial Office at pmrjournal@wiley.com
For queries about your article after acceptance, please contact the Production Editor at PMRJ@wiley.com
Author Guidelines updated July 5, 2020
